[{"id":"8c229a43-88ef-4aa6-9cca-dad9d1af3b1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03457142","created_at":"2021-01-18T17:02:40.865Z","updated_at":"2025-02-25T14:38:10.967Z","phase":"Phase 2","brief_title":"Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy","source_id_and_acronym":"NCT03457142","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IL6 • CD28 • CD86","pipe":" | ","alterations":" CD28 expression • IL6 expression","tags":["IL6 • CD28 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD28 expression • IL6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ninlaro (ixazomib) • Orencia (abatacept)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/11/2018","start_date":" 09/11/2018","primary_txt":" Primary completion: 11/21/2022","primary_completion_date":" 11/21/2022","study_txt":" Completion: 01/11/2025","study_completion_date":" 01/11/2025","last_update_posted":"2024-05-16"},{"id":"0130cadc-804e-436f-a2b2-19a2f539a6a6","acronym":"NCI-2018-03732","url":"https://clinicaltrials.gov/study/NCT03786783","created_at":"2021-01-18T18:43:54.532Z","updated_at":"2024-07-02T16:35:09.101Z","phase":"Phase 2","brief_title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","source_id_and_acronym":"NCT03786783 - NCI-2018-03732","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYCN • IL6 • CXCL9","pipe":" | ","alterations":" MYCN amplification • IL6 expression","tags":["MYCN • IL6 • CXCL9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • IL6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • cyclophosphamide intravenous • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/04/2019","start_date":" 03/04/2019","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-04-17"},{"id":"2336543a-dcf9-430c-b379-3ba681cf6a7e","acronym":"ATROMAB","url":"https://clinicaltrials.gov/study/NCT06077734","created_at":"2023-10-11T16:12:37.535Z","updated_at":"2024-07-02T16:35:33.864Z","phase":"","brief_title":"Muscle Stem Cell Quality in Atrophy","source_id_and_acronym":"NCT06077734 - ATROMAB","lead_sponsor":"Maastricht University Medical Center","biomarkers":" IL6 • HMGB1","pipe":" | ","alterations":" IL6 expression","tags":["IL6 • HMGB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL6 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-10-11"},{"id":"539c3099-b137-489d-b199-cc2e1c062cbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04601961","created_at":"2021-01-19T20:30:39.168Z","updated_at":"2024-07-02T16:35:51.772Z","phase":"","brief_title":"Effects of TIVA Versus Inhalational Anaesthesia on Circulating Tumour Cells in Hepatocellular Carcinoma Patients","source_id_and_acronym":"NCT04601961","lead_sponsor":"The University of Hong Kong","biomarkers":" IL6 • TNFA • HIF1A • CRP","pipe":" | ","alterations":" HIF1A expression • IL6 expression","tags":["IL6 • TNFA • HIF1A • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HIF1A expression • IL6 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 03/31/2024","study_completion_date":" 03/31/2024","last_update_posted":"2023-03-31"},{"id":"74e48d1c-cb70-48fe-88e1-ed26165595f6","acronym":"BASALT","url":"https://clinicaltrials.gov/study/NCT04554771","created_at":"2021-01-18T21:46:29.704Z","updated_at":"2024-07-02T16:35:58.934Z","phase":"Phase 2","brief_title":"Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy","source_id_and_acronym":"NCT04554771 - BASALT","lead_sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","biomarkers":" IL6 • ADAM12","pipe":" | ","alterations":" IL6 expression","tags":["IL6 • ADAM12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Actemra IV (tocilizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 01/27/2021","start_date":" 01/27/2021","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2022-12-19"},{"id":"49dcbbff-6ced-48b8-82ea-1df1dba75ce8","acronym":"BAZE","url":"https://clinicaltrials.gov/study/NCT04812808","created_at":"2021-03-24T16:10:47.311Z","updated_at":"2024-07-02T16:36:16.409Z","phase":"","brief_title":"Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT04812808 - BAZE","lead_sponsor":"Hôpital Fribourgeois","biomarkers":" IL6 • STAT3","pipe":" | ","alterations":" STAT3 expression • IL6 expression","tags":["IL6 • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STAT3 expression • IL6 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2022","start_date":" 02/01/2022","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 05/31/2024","study_completion_date":" 05/31/2024","last_update_posted":"2022-02-25"},{"id":"3e5dc172-f549-4905-9ea9-ff667d3c69f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02647775","created_at":"2021-01-18T12:53:04.374Z","updated_at":"2024-07-02T16:36:51.060Z","phase":"","brief_title":"Hemodynamic and Inflammatory Responses in Thoracic Surgery","source_id_and_acronym":"NCT02647775","lead_sponsor":"Chang Gung Memorial Hospital","biomarkers":" IL6 • CRP","pipe":" | ","alterations":" IL6 expression","tags":["IL6 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL6 expression"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2020-01-22"},{"id":"3e9f16ba-7ef3-4a62-bda2-2d123d6d52a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03965546","created_at":"2021-01-18T19:30:34.813Z","updated_at":"2024-07-02T16:36:57.170Z","phase":"Phase 1","brief_title":"ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer","source_id_and_acronym":"NCT03965546","lead_sponsor":"First Affiliated Hospital Xi'an Jiaotong University","biomarkers":" HLA-A • IFNG • IL6 • TNFA • AFP • IL2 • IL10","pipe":" | ","alterations":" HLA-A*02 • AFP expression • IL10 elevation • IL2 expression • IL6 expression","tags":["HLA-A • IFNG • IL6 • TNFA • AFP • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • AFP expression • IL10 elevation • IL2 expression • IL6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • ET1402L1-ARTEMIS T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 27","initiation":"Initiation: 05/30/2019","start_date":" 05/30/2019","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2019-08-08"},{"id":"7f0df80d-70ad-4190-bdfa-2754e6ffaf20","acronym":"","url":"https://clinicaltrials.gov/study/NCT01028001","created_at":"2021-01-18T04:02:07.344Z","updated_at":"2024-07-02T16:37:28.317Z","phase":"Phase 2","brief_title":"Preoperative Soy Isoflavone Supplementation in the Prevention of Head and Neck Squamous Carcinoma","source_id_and_acronym":"NCT01028001","lead_sponsor":"University of Michigan Cancer Center","biomarkers":" EGFR • VEGFA • IL6 • BCL2L1 • PTGS2","pipe":" | ","alterations":" EGFR expression • TP53 expression • IL6 expression","tags":["EGFR • VEGFA • IL6 • BCL2L1 • PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • TP53 expression • IL6 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 02/01/2010","start_date":" 02/01/2010","primary_txt":" Primary completion: 12/01/2014","primary_completion_date":" 12/01/2014","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2016-10-24"}]